Analysis of data from the Genomics of Drug Sensitivity in Cancer Project database also showed FLT3-mutated (point mutations and/or copy number alterations) cells derived from patients with various solid tumors and leukemias as a group to be differentially sensitive to single agents targeting AURORA kinases and AKT (Figure S7). This evidence concerns the gene AKT1 and leukemia.